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Background: The media plays a role in shaping opinions about medical decisions, for example, 
whether to initiate or stop treatment. An association between negative media attention and statin 
discontinuation has been demonstrated, but it may differ depending on the reason for prescrip-
tion and whether the user is new (incident) or long term (prevalent).
Aim: The aim of this study is to explore whether a Danish newspaper article featuring the side 
effects of statins affects statin discontinuation in incident versus prevalent users, with the reason 
for prescription also taken into account.
Methods: The study relies on a quasi-experimental design and uses registry data on statin 
purchases to explore discontinuation and treatment duration. As a proxy for reason for pre-
scription, data on filled prescriptions and hospital diagnoses from a Danish registry were used. 
We compared statin discontinuation in all statin users in Denmark in 2007 before the media 
event (n=343,438) and after it in 2008 (n=404,052).
Results: Compared to 2007, statin discontinuation among prevalent users in 2008 increased 
by 2.97 percentage points (pp). The change in discontinuation varied with the indication 
for statin use. Those with myocardial infarction had the smallest increase (1.98 pp) and 
those with hypercholesterolemia or primary hypertension had the largest increase (3.54 pp). 
Incident statin users had a higher level of discontinuation and a larger difference in dis-
continuation between 2007 and 2008. Compared to 2007, more people (5.52 pp) discon-
tinued statin treatment in 2008. Again, those with myocardial infarction had the smallest 
decrease in statin discontinuation (1.49 pp), while those with a potential atherosclerotic 
condition (7.05 pp) and hypercholesterolemia or primary hypertension (6.10 pp) had the 
largest increase.
Conclusion: Statin discontinuation increased in 2008 following a media event, but especially 
among individuals prescribed statins for primary prevention and among new statin users.
Keywords: statin discontinuation, media attention, quasi-experimental study, primary 
prevention, secondary prevention
Background
Statins, also known as HMG-CoA reductase inhibitors, were initially introduced on 
the market as lipid-lowering drugs to reduce mortality after myocardial infarction (MI) 
in middle-aged men with hypercholesterolemia.1 Since then, recommendations for 
prescribing statins have gradually expanded,2 first to include patients (independently 
of sex and age) with different categories of atherosclerotic cardiovascular diseases 
(CVDs) and diabetes, and then to include individuals assessed as being at high risk of 
developing CVDs.3,4 Since the introduction of statins, patent expirations have led to 
declining consumer prices, while policies regulating consumer costs promoted statin 
use across Europe.5 The widening of prescription criteria, together with a decline in 
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prices, has led to a large increase in the use of statins.6 Today, 
statins are among the most prescribed medications globally.7,8 
In Denmark, simvastatin and pravastatin were approved in 
the early 1990s. The use of statins, however, was rare until 
1994, when international research, international guidelines, 
national guidelines and reimbursement policies promoted 
their use.4,9
While statin therapy is, in principle, lifelong, about 50% 
stop refilling their prescriptions within the first year.10 General 
practitioners (GPs) are generally hesitant to stop treatment.11 
Hence, the decision to discontinue taking statins is often made 
by the statin user, which is called nonadherence.12,13 Statin 
users are faced with the challenge of balancing information 
on the potential benefits and harms of statin treatment. Side 
effects and fear of side effects play a major role in the deci-
sion to discontinue statins.14 The mass media has repeatedly 
focused on the negative side effects of statins and other 
medications. This information is likely to influence the choice 
to discontinue using statins.
In Denmark the tabloid newspaper “BT” has on several 
occasions reported adverse effects of statins.15 Especially, 
after an article was published on July 23, 2008, the Danish 
Medicines Agency registered a marked increase in the report-
ing of statin-related adverse effects. The media not only plays 
an agenda-setting role in defining which topics people think 
and talk about but also lays the frame how to think about 
a given topic. Recent research on framing highlights that 
attitudes are shaped by the active processing of information 
from the media, as well as by discussing this information 
with, for example, peers.16
A most well-documented example of media influence on 
health behavior is the association between media coverage of 
suicides and new suicide cases.17 Few studies investigated the 
association between media attention and use of medications. 
A British study found a decline in the use of antidepres-
sants following adverse media publicity.18 A Swedish study 
investigated the framing of articles on an antiobesity drug 
and found that positive framing coincided with the launch 
of the drug.19 Studies investigating the association between 
media attention and hormone therapy found that medical 
decisions are influenced by media exposure and framing.20 
Recently, some studies focused on the association between 
media reporting and statin use. Nielsen and Nordestgaard 
found increased early statin discontinuation in Denmark 
after exposure to negative media attention on statins. They 
followed, however, individuals in the early phase of statin 
use (incident users), where most discontinuation occurs.21 
Statin intolerance, which is a major reason for statin 
discontinuation, often has its onset within the first month 
of use.22,23 Long-term users (prevalent users) have incorpo-
rated statin use into their daily lives and may be less likely to 
be influenced by negative media events. Furthermore, statin 
users who have CVD or diabetes have stronger incentives to 
continue treatment, regardless of negative media coverage of 
statins. A British study, however, found an equal likelihood 
of stopping after media attention in primary and secondary 
care patients,24 while an Australian study found that those 
who used more cardiovascular drugs were less likely to 
stop.25 As a result, the extent to which media attention affects 
incident and prevalent users in different ways, and according 
to the indication for statin use, is unclear.
The aim of this study is to explore whether a Danish 
newspaper article featuring the side effects of statins affects 
statin discontinuation in incident versus prevalent users, with 
the reason for prescription also taken into account.
Methods
Quasi-experimental study designs take advantage of events 
such as changes in legislation, policies and prices and 
examine the effects in either exposed and unexposed, or 
before and after the societal experiment, without interfering 
in the experiment.26,27 In this study, we explore the effects 
of a 2008 media event featuring statin side effects on statin 
discontinuation by comparing discontinuation before (2007) 
and after (2008) the event. There is a temporal variation in 
statin purchases in Denmark, where the number of purchases 
is 9% lower in July compared to the average in the other 
11 months (based on own data). We assume that those with 
newly diagnosed MI are, however, equally likely to initiate 
statin treatment during summer, but this subpopulation is 
a minority of the total population of statin users. This dif-
ference is most likely due to the fact that July is the peak 
of the summer holiday season. To avoid any impact due to 
season, we compared data from the same months in both 
2007 and 2008.
When using a quasi-experimental study design, the goal 
is not to rule out confounding factors from other factors in 
conventional statistical analyses. Instead, the plausibility of 
the design has to be tested by arguments that rule out alterna-
tive explanations. First, changes in the pattern of statin use 
could be influenced by changes in policies or prices. No shifts 
in policies occurred between 2007 and 2008, and no major 
changes in consumer prices occurred in the same period; 
however, the long-term trend shows a decline in prices, 
which would lead to less statin discontinuation. In addition, 
the financial crisis may have led to a general decrease in 
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consumption, including a decline in the consumption of 
medicines. To test this, we compared statin discontinuation 
with antihypertensive discontinuation in a similar design.
Data
The study was based on administrative registry databases at 
Statistics Denmark covering the entire Danish population, 
allowing researchers to combine information at the indi-
vidual level by means of an encrypted person identifier.28 
We retrieved registry information on purchased prescriptions 
from the Danish National Prescription Registry,29 which 
contains information on prescription medication purchased 
at Danish pharmacies from 1995 and onward. Each prescrip-
tion record includes the prescription date and the Anatomical 
Therapeutic Chemical classification codes.30,31 Information 
on hospitalizations (eg, discharge diagnoses) was retrieved 
from the Danish National Patient Registry and applied for 
the registry-based indication proxy (see below). Information 
on age and sex was available from this registry through the 
encrypted person identifier.
ethics
Use of Danish registry data does not require permission from 
ethics committees or the Danish Data Protection Agency. 
However, all data processing must be done on servers at 
Statistics Denmark, and no individual level data may be 
transferred outside this protected environment. Moreover, 
individual data is de-identified to researchers, and aggregate 
tables are not allowed to have cell counts of less than five in 
order to ensure anonymity.
study cohorts
Two study cohorts were created. The first one comprised 
all residents of Denmark with at least one statin purchase 
between January and June 2007. This cohort was further 
divided into prevalent statin users (first statin purchase 
before 2007) and incident statin users (new users in 2007). 
A corresponding cohort with at least one statin purchase 
between January and June 2008 was also established. We 
excluded individuals with ,10 years residence before 
2007/2008 because we wished to track their hospitalizations 
and medicine use. Furthermore, individuals who died in 2007 
were excluded from the 2007 cohort, and those who died in 
2008 were excluded from the 2008 cohort. Figure 1 describes 
the inclusion and exclusion criteria of participants in detail. 
Finally, the 2007 study cohort consisted of 305,952 prevalent 
users and 37,486 incident users, while the 2008 cohort com-
prised 361,701 prevalent users and 42,351 incident users.
statin discontinuation
Statin discontinuation, the outcome, was defined as no sta-
tin purchases from August to December. Using this simple 
approach, we assumed that tablets from previous statin pur-
chases had been ingested. This approach shares the assump-
tions of the refill persistence approach, but avoids overtly 
strong assumptions about the precision of the method and to 
circumvent seasonal influence on adherence measures.32
covariates
Analyses were stratified according to sex, age (#59, 
60+ years), and indication for statin use. In accordance with 
Wallach-Kildemoes et al,33 a grouped version of the indica-
tion hierarchy was used to classify indication for statin use, 
with a combination of hospital and prescription information 
for the past 10 years also included. The indications were 
grouped as 1) primary prevention: hypercholesterolemia 
(ie, no registry information) or primary hypertension; 
2) diabetes; 3) potential atherosclerotic condition (PAC); 
4) peripheral arterial disease (PAD), stroke, or ischemic heart 
disease (IHD) without MI; and 5) acute MI. PAC covers the 
gray zone conditions not included as indications in statin 
guidelines. Individuals were classified on 1 July in 2007 and 
2008, according to their highest number in the five groups.
statistical analyses
We calculated discontinuation as the proportion in each year 
of those who did not have an additional statin purchase from 
August to December and 95% confidence interval. Differ-
ences in discontinuation between 2007 and 2008 were stated 
in percentage points (pp). The two-sided P-values comparing 
adherence in 2007 and 2008 were calculated. Separate analy-
ses, stratified according to age, sex, and indication for statin 
use, were carried out for incident and prevalent users.
sensitivity analyses
In order to study if any associations were part of a general 
change in prescribing or purchasing patterns due to for exam-
ple business cycles, we compared purchases of statins with 
purchases of antihypertensives. The datasets and analyses 
for antihypertensives that we constructed were analogous to 
those for statins. We also analyzed the purchase of statins 
in 2009 to study if any changes remained over time. SAS 
statistical software 9.4 was used for all analyses.
Results
Table 1 shows an analysis of discontinuation among preva-
lent statin users. In the fall of 2007, 7.22% discontinued 
statins, which increased to 10.25% in 2008, corresponding 
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to an increase of 2.97 pp. The increase was almost identical 
in men (2.98 pp) and women (2.96 pp), and in statin users 
aged #59 years (3.20 pp) versus those aged $60 years 
(3.38 pp). Changes in statin discontinuation varied with the 
reason for prescription. Those with hypercholesterolemia 
or primary hypertension had the largest increase in discon-
tinuation (3.54 pp), whereas those with MI had the smallest 
increase (1.98 pp). Those with diabetes also had a relatively 
small increase (2.34 pp). Individuals with PAC had an 
increase of 3.24 pp and those with PAD, stroke, or IHD had 
an increase of 2.77 pp.
Table 2 shows the same analysis, but among the inci-
dent statin users, who had a higher level of discontinuation 
and a larger difference in discontinuation between 2007 
and 2008. While 16.86% of statin users discontinued 
purchasing statins in the fall of 2007, the discontinuation 
increased to 22.38% in 2008, corresponding to an increase 
of 5.52 pp. The increase was similar in men (5.07 pp) 
and women (5.66 pp), and in younger (5.01 pp) and older 
(5.52 pp) statin users. As for the prevalent users, the 
increase in statin discontinuation varied with the reason 
for prescription. Those with PAC had the largest increase 
Figure 1 Flowchart of participants.
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(7.05 pp), followed by those with hypercholesterolemia or 
primary hypertension (6.1 pp). Statin users with MI had 
the smallest increase (1.49 pp), while those with diabetes 
had a increase of 3.39 pp and those with PAD, stroke, or 
IHD a increase of 4.04 pp.
results of sensitivity analyses
The discontinuation of antihypertensives was 5.75 
(5.70–5.80) in 2007 and almost identical in 2008 5.65 
(5.60–5.70) and, hence, was presumably not influenced 
by the statin-related media event. Statin discontinuation in 
2009 was 9.43 (90.48–90.66) for prevalent statin users and 
20.5 (20.06–20.95) for incident statin users, which means a 
decrease compared to 2008, but still at a higher level com-
pared to 2007. Hence, statin discontinuation did not return 
to the level before the news event.
Discussion
Both incident and prevalent users were sensitive to media 
coverage on statin side effects, but incident statin users were 
more sensitive than prevalent users. Likewise, individuals 
prescribed statins for primary prevention (ie, without estab-
Table 1 statin discontinuation in 2007 and 2008 by prevalent statin users and their change in discontinuation between 2007 and 2008
Variable (levels) 2007 2008 Difference 2007 
versus 2008
P-value
% with discontinuation (95% CI) % with discontinuation (95% CI) pp
All prevalent statin users 7.22 (7.19–7.38) 10.25 (10.18–10.35) +2.97 ,0.0001
Age, years
#59 8.78 (8.57–9.00) 11.98 (11.74–12.21) +3.20 ,0.0001
$60 6.42 (6.34–6.52) 9.80 (9.69–9.91) +3.38 ,0.0001
sex
Men 7.43 (7.30–7.56) 10.41 (10.29–10.55) +2.98 ,0.0001
Women 7.12 (6.98–7.25) 10.08 (9.94–10.22) +2.96 ,0.0001
indication for statin use
hypercholesterolemia 
or primary hypertension
7.58 (7.43–7.73) 11.12 (10.96–11.28) +3.54 ,0.0001
Diabetes 8.04 (7.72–8.37) 10.38 (10.97–10.72) +2.34 ,0.0001
PAc 7.28 (6.88–7.68) 10.52 (10.07–10.95) +3.24 ,0.0001
PAD, stroke, or ihD 7.19 (7.03–7.36) 9.96 (9.78–10.14) +2.77 ,0.0001
Myocardial infarction 6.36 (6.15–6.67) 8.34 (8.11–8.57) +1.98 ,0.0001
Abbreviations: ihD, ischemic heart disease; PAc, potential atherosclerotic condition; PAD, peripheral arterial disease; pp, percentage points.
Table 2 statin adherence in 2007 and 2008 by incident statin users and their change in adherence between 2007 and 2008
Variable (levels) 2007 2008 Difference 2007 
versus 2008
P-value
% with discontinuation (95% CI) % with discontinuation (95% CI) pp
All prevalent statin users 16.86 (16.49–17.24) 22.38 (21.98–22.78) +5.52 ,0.0001
Age, years
#59 18.74 (18.01–19.48) 23.75 (23.00–24.50) +5.01 ,0.0001
$60 16.10 (15.66–16.54) 21.62 (21.18–22.06) +5.52 ,0.0001
sex
Men 17.10 (16.56–17.65) 22.17 (21.60–22.75) +5.07 ,0.0001
Women 16.64 (82.83–83.88) 22.30 (21.75–22.84) +5.66 ,0.0001
indication for statin use
hypercholesterolemia 
or primary hypertension
82.90 (16.60–17.60) 23.20 (22.69–23.70) +6.10 ,0.0001
Diabetes 18.56 (16.98–20.04) 21.95 (20.15–23.75) +3.39 0.0059
PAc 16.65 (15.10–18.20) 23.70 (22.07–25.34) +7.05 ,0.0001
PAD, stroke, or ihD 17.19 (16.37–18.01) 21.23 (20.35–22.12) +4.04 ,0.0001
Myocardial infarction 12.64 (11.38–13.89) 14.13 (12.78–15.49) +1.49 ,0.0001
Abbreviations: ihD, ischemic heart disease; PAc, potential atherosclerotic condition; PAD, peripheral arterial disease; pp, percentage points.
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lished CVD or diabetes) were more sensitive to the media 
event than those prescribed statin after MI.
Another Danish study reported that patients newly ini-
tiating statin therapy (incident users) were less likely to fill 
a second prescription, if media stories in the period imme-
diately afterward were dominated more by negative rather 
than positive statin stories.21 We not only found that incident 
statin users were more susceptible to media coverage, but 
also to changes (though small) in discontinuation in prevalent 
statin users. This indicates that new users who have not yet 
incorporated statin use in their daily lives are more likely to 
be influenced by mass media when deciding whether to stop 
statin treatment.
A British study of primary care patients found that statin 
users in both primary and secondary prevention were equally 
more likely to stop statin treatment after a highly negative 
media coverage period than without such exposure.24 The 
odds of stopping were almost identical in primary and 
secondary prevention patients, which is in contrast to this 
Danish study. This discrepancy can perhaps be explained 
by the different definitions applied to primary and secondary 
prevention in the British study compared to ours. While a 
range of CVDs was included to define secondary prevention 
in the British study, we subdivided individuals with estab-
lished CVD into three groups. In our study, statin users with 
diabetes constituted a separate group, but the British study 
included statin users with diabetes in its primary prevention 
group. Similar to our study, there were no sex differences; 
but unlike our study, older individuals were more likely 
to stop.24
An Australian study on the short-term effects of a TV 
program containing criticism about certain aspects of statins 
showed an increase in the discontinuation of statins in the 
week of the program (long-term effects not studied), with a 
larger impact found on individuals who did not take diabetes 
drugs or any other cardiovascular drugs.34 Their assessment 
points in the same direction as this study, albeit with different 
measures of indication for statin use. The studies mentioned 
differ in general design, in measurement of media attention, 
and in statin use, which means they are not entirely compa-
rable to this study; nevertheless, they all point to a similar 
finding: that mass media coverage of statins influences 
patterns of statin use.
Our study indicates that people are particularly sensitive 
to the media focus on side effects when their medication 
is not incorporated as a part of daily life (incident users), 
as are individuals without CVD or diabetes, that is, people 
prescribed statin therapy based on a risk assessment. Both 
groups may be more likely to consider whether the benefits 
outweigh the harm, concluding that that risk of the medicine 
being a daily nuisance is too high a price for possible post-
ponement of CVD.
strengths and limitations
This study was based on registry data on the entire popula-
tion of statin users, which means that there was no loss to 
follow-up and that measures were free of any bias stemming 
from self-reporting. This study also contains detailed infor-
mation on hospitalizations and use of cardiovascular and 
diabetes drugs, enabling us to distinguish between subgroups 
of indication of statin use.
Registry data does not, however, include any specific 
reason for discontinuation. Analyses are based on purchases, 
and the extent of the GPs’ role in the amount prescribed is 
unknown. A study on statin discontinuation among Danish 
GPs found that they are generally reluctant to stop statin 
treatment, but that statin cessation may be a joint decision.11 
In addition, information on conditions not included in the 
registry, such as familial hypercholesterolemia, is likely to 
affect positively decisions on continued statin therapy. By 
using a quasi-experimental design, this study differs from 
studies using conventional cohort designs. Instead of con-
trolling for potential confounding factors using regression 
models, the argument for causal association relies on the 
assumption that Danish statin users were comparable in 
2007 and 2008, apart from the media event. This approach 
relies on other factors, such as policies and prices being 
equal. The financial crisis led to a general decrease in 
consumption and could have also led to a decline in the 
sale of statins. Since the purchase of antihypertensives was 
unaffected, we assume that this was not the case. Overall, 
the use of various methodological approaches is one of 
the strengths of the emerging field of media influence on 
medicine use.
Conclusion
Statin discontinuation increased in 2008 following a media 
event, but especially among individuals prescribed statins for 
primary prevention. Incident satin users had a larger increase 
in statin discontinuation compared to prevalent statin users. 
The results may reflect the fact that medicine users weighed 
the benefits of medicine therapy compared to its side effects 
during intense media attention on the side effects of statins. 
Prevalent statin users seem less prone to consider whether 
or not therapy is worthwhile.
Disclosure
The authors report no conflicts of interest in this work.
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